NKGen Biotech amends convertible loan deal with AlpineBrook, adds USD 1.05 million note
NKGN•Consideration shares and warrant terms updated
Consideration shares to the lender increased to 13,304,114, scheduled for delivery in six installments over 30 months from the loan closing.
The company also issued Additional Warrant #4 with a USD 0.08 exercise price; term 10 years; includes cashless exercise and a 9.99% ownership cap.
Amended convertible loan agreement adds additional note
NKGen Biotech amended its secured convertible loan agreement with AlpineBrook Capital on Aug. 5, 2026.
The Fourth Amendment adds an additional loan of USD 1.05 million, including a USD 95,500 facilitation fee; net proceeds are USD 955,000.
Additional Note #4 converts into common stock at USD 0.08 per share, subject to adjustment; interest accrues at the Loan Agreement’s applicable rate.
